How to use Itovebi (inavolisib)-u200c inaliside

Patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer will be selected for treatment withItovebi (inavolisib) based on the presence of one or morePIK3CA mutations in their plasma specimens. Assess fasting plasma glucose (FPG)/blood glucose (FBG) and hemoglobin A1C (HbA1C) before starting Itovebi and periodically during treatment, and optimize blood glucose.

Itovebiis available in tablet form and the recommended dose is 9 mg taken orally once daily with or without food until disease progression or unacceptable toxicity. When coadministering Itovebi with palbociclib and fulvestrant, the recommended dose of palbociclib is 125 mg orally administered once daily for 21 days, followed by 7 days off treatment, forming a 28-day cycle. Patients take Itovebi at approximately the same time each day. Swallow tablets whole without chewing, crushing or breaking them apart before swallowing.

For premenopausal and perimenopausal women, use luteinizing hormone-releasing hormone (LHRH) agonists according to local clinical practice. For men, consider using an LHRH agonist according to local clinical practice. If the patient misses a dose, instruct the patient to take the missed dose as soon as possible within 9 hours. After 9 hours have elapsed, instruct patients to skip the dose and take the next dose at the scheduled time. If the patient vomits a dose, instruct the patient not to take additional doses that day and to continue the regular dosing schedule the next day.

To control adverse effects, consider interrupting treatment or reducing the dose. It is recommended that the initial dose be reduced to orally once a day6mg;if further dose reduction is necessary, reduce the dose to orally once a day3mg. The recommended starting dose of Itovebifor patients with moderate renal impairment (based on CKD-EPI, eGFR 30 to <60 mL/min) is 6 mg orally once daily.